Sep 15, 2023 · Eosinophilic esophagitis (EoE) is a chronic disease mediated by environmental allergens and type 2 immune inflammation, which causes significant symptoms including …

Learn more about DUPIXENT® (dupilumab), the first FDA-approved biologic to treat eosinophilic esophagitis (EoE) in adult and pediatric patients aged 1 year and older who weigh at least 33lb …

Jan 1, 2023 · Eosinophilic esophagitis (EoE) is a chronic, allergen-mediated, eosinophil-predominant, type 2 inflammatory disease that progresses to fibrostenosis of the esophagus if …

Dec 21, 2024 · Our findings suggest that the biologics currently being investigated are considered safe and effective treatments for EoE, while their efficiency varies. However, the discussion of …

Feb 20, 2024 · The Consumer’s Guide to Biologics for Eosinophilic Esophagitis Learn everything you need to know about the first FDA-approved treatment for eosinophilic esophagitis.

Jun 12, 2024 · Dupixent is an injectable biologic medicine. Here’s how it helps with eosinophilic esophagitis.

2 days ago · More recently, biologic therapies have emerged as a promising treatment option. While dietary modifications, PPIs, and corticosteroids remain first-line treatments, the …

Dec 21, 2024 · Objective Advancing the understanding of the pathophysiology of eosinophilic oesophagitis (EoE) and other eosinophilic gastrointestinal diseases (EGIDs) has spurred …

Explore the evolution of pharmacologic treatments for eosinophilic esophagitis (EoE), including proton pump inhibitors, topical corticosteroids, and biologic agents, highlighting advancements …

Feb 25, 2023 · The recent approval of dupilumab for treatment of eosinophilic esophagitis (EOE), research into better biomarkers, and the anticipated availability of a metric to assess EOE …